SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jasvinder A. Singh, Nipam Shah, N. Lawrence Edwards, A cross-sectional internet-based patient survey of the management strategies for gout, BMC Complementary and Alternative Medicine, 2016, 16, 1

    CrossRef

  2. 2
    Puja Khanna, Dinesh Khanna, Chris Storgard, Scott Baumgartner, Robert Morlock, A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift, Postgraduate Medicine, 2016, 128, 1, 34

    CrossRef

  3. 3
    R L Roberts, M C Wallace, A J Phipps-Green, R Topless, J M Drake, P Tan, N Dalbeth, T R Merriman, L K Stamp, ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout, The Pharmacogenomics Journal, 2016,

    CrossRef

  4. 4
    Pinky Dua, Rachel Gurrell, Simon Kirby, Maria Sudworth, Peter T. Loudon, Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649, Clinical Rheumatology, 2016,

    CrossRef

  5. 5
    Lisa K. Stamp, Peter T. Chapman, Suetonia C. Palmer, Allopurinol and kidney function: An update, Joint Bone Spine, 2016, 83, 1, 19

    CrossRef

  6. 6
    Jonathan Paraskos, Zsofia Berke, Jason Cook, Jeffrey N. Miner, Martin Braddock, Adam Platt, Glen Hughes, An analytical comparison between point-of-care uric acid testing meters, Expert Review of Molecular Diagnostics, 2016, 16, 3, 373

    CrossRef

  7. 7
    Mariann Harding, An update on gout for primary care providers, The Nurse Practitioner, 2016, 41, 4, 14

    CrossRef

  8. 8
    Wichittra Tassaneeyakul, Napat Prabmeechai, Chonlaphat Sukasem, Thachanan Kongpan, Parinya Konyoung, Pansu Chumworathayi, Somsak Tiamkao, Usanee Khunarkornsiri, Kongkiat Kulkantrakorn, Niwat Saksit, Nontaya Nakkam, Patompong Satapornpong, Suda Vannaprasaht, Alisara Sangviroon, Surakameth Mahasirimongkol, Nuanjun Wichukchinda, Ticha Rerkpattanapipat, Wongwiwat Tassaneeyakul, Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population, Pharmacogenetics and Genomics, 2016, 26, 5, 225

    CrossRef

  9. 9
    Sirisha Mitnala, Amanda Phipps-Green, Christopher Franklin, Anne Horne, Lisa K. Stamp, Tony R. Merriman, Nicola Dalbeth, Clinical and genetic features of diuretic-associated gout: a case-control study, Rheumatology, 2016, kew018

    CrossRef

  10. 10
    Keith Rome, Kathryn Erikson, Cynthia Otene, Hazra Sahid, Karyn Sangster, Peter Gow, Clinical characteristics of foot ulceration in people with chronic gout, International Wound Journal, 2016, 13, 2
  11. 11
    Chang-Fu Kuo, Matthew J Grainge, Christian Mallen, Weiya Zhang, Michael Doherty, Comorbidities in patients with gout prior to and following diagnosis: case-control study, Annals of the Rheumatic Diseases, 2016, 75, 1, 210

    CrossRef

  12. 12
    Ghaith Mitri, Eric T. Wittbrodt, Robin S. Turpin, Beni A. Tidwell, Kathy L. Schulman, Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease, Journal of Managed Care & Specialty Pharmacy, 2016, 22, 4, 326

    CrossRef

  13. 13
    Hyo Jin Choi, Chan Hee Lee, Joo Hyun Lee, Bo Young Yoon, Hyoun Ah Kim, Chang Hee Suh, Sang Tae Choi, Jung Soo Song, Ho Yeon Joo, Sung Jae Choi, Ji Soo Lee, Kee Chul Shin, Han Joo Baek, Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares, International Journal of Rheumatic Diseases, 2016, 19, 4
  14. 14
    Hugh de Lautour, William J. Taylor, Ade Adebajo, Rieke Alten, Ruben Burgos-Vargas, Peter Chapman, Marco A. Cimmino, Geraldo da Rocha Castelar Pinheiro, Ric Day, Leslie R. Harrold, Philip Helliwell, Matthijs Janssen, Gail Kerr, Arthur Kavanaugh, Dinesh Khanna, Puja P. Khanna, Chingtsai Lin, Worawit Louthrenoo, Geraldine McCarthy, Janitzia Vazquez-Mellado, Ted R. Mikuls, Tuhina Neogi, Alexis Ogdie, Fernando Perez-Ruiz, Naomi Schlesinger, H. Ralph Schumacher, Carlo A. Scirè, Jasvinder A. Singh, Francisca Sivera, Ole Slot, Lisa K. Stamp, Anne-Kathrin Tausche, Robert Terkeltaub, Till Uhlig, Mart van de Laar, Douglas White, Hisashi Yamanaka, Xuejun Zeng, Nicola Dalbeth, Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises, Arthritis Care & Research, 2016, 68, 5
  15. 15
    Akarin Hiransuthikul, Thanapoom Rattananupong, Jettanong Klaewsongkram, Pawinee Rerknimitr, Marisa Pongprutthipan, Kiat Ruxrungtham, Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS): 11 years retrospective study in Thailand, Allergology International, 2016,

    CrossRef

  16. 16
    Sarah C. Metzger, Michaela Koehm, Julian L. Wichmann, Stefan Buettner, Jan-Erik Scholtz, Martin Beeres, J. Matthias Kerl, Moritz H. Albrecht, Renate Hammerstingl, Thomas J. Vogl, Ralf W. Bauer, Dual-Energy CT in Patients with Suspected Gouty Arthritis:, Academic Radiology, 2016, 23, 3, 267

    CrossRef

  17. 17
    Kasper Søltoft Larsen, Anton Pottegård, Hanne M. Lindegaard, Jesper Hallas, Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study, The American Journal of Medicine, 2016, 129, 3, 299

    CrossRef

  18. 18
    Fernando Perez-Ruiz, Irati Urionagüena, Loreto Carmona-Ortells, Epidemiology and health-related services, Current Opinion in Rheumatology, 2016, 28, 2, 104

    CrossRef

  19. 19
    Lee J. Smolen, James C. Gahn, Ghaith Mitri, Aki Shiozawa, Febuxostat in the management of gout: a cost-effectiveness analysis, Journal of Medical Economics, 2016, 19, 3, 265

    CrossRef

  20. 20
    Nicola Dalbeth, Tony R Merriman, Lisa K Stamp, Gout, The Lancet, 2016,

    CrossRef

  21. 21
    Jasvinder A. Singh, Shaohua Yu, Gout-related inpatient utilization: a study of predictors of outcomes and time trends, Arthritis Research & Therapy, 2016, 18, 1

    CrossRef

  22. 22
    Tim Finkenstaedt, Andrei Manoliou, Martin Toniolo, Kai Higashigaito, Gustav Andreisek, Roman Guggenberger, Beat Michel, Hatem Alkadhi, Gouty arthritis: the diagnostic and therapeutic impact of dual-energy CT, European Radiology, 2016,

    CrossRef

  23. 23
    Nishanthinie Parathithasan, Wai-Kit Lee, Marcus Pianta, Shereen Oon, Warren Perera, Gouty arthropathy: Review of clinico-pathologic and imaging features, Journal of Medical Imaging and Radiation Oncology, 2016, 60, 1
  24. 24
    Juan García Puig, Eugenio de Miguel, Hiperuricemia y gota: impacto de la ecografía, Medicina Clínica, 2016, 146, 2, 67

    CrossRef

  25. 25
    Hye Jung Park, Young Joo Kim, Dong Hyun Kim, Junho Kim, Kyung Hee Park, Jung-Won Park, Jae-Hyun Lee, HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs, Yonsei Medical Journal, 2016, 57, 1, 118

    CrossRef

  26. 26
    M. A. Reuss-Borst, Hyperurikämie, Der Internist, 2016, 57, 2, 194

    CrossRef

  27. 27
    Chang-Fu Kuo, Matthew J. Grainge, Christian Mallen, Weiya Zhang, Michael Doherty, Impact of gout on the risk of atrial fibrillation, Rheumatology, 2016, 55, 4, 721

    CrossRef

  28. 28
    Zancong Shen, Li-Tain Yeh, Kathleen Wallach, Nanqun Zhu, Brad Kerr, Michael Gillen, In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters, Clinical Drug Investigation, 2016,

    CrossRef

  29. 29
    Nicholas J. Kennedy, Paul J. Healy, Andrew A. Harrison, Inpatient management of gout in a New Zealand hospital: a retrospective audit, International Journal of Rheumatic Diseases, 2016, 19, 2
  30. 30
    Bart Spaetgens, Tobias Pustjens, Lieke E. J. M. Scheepers, Hein J. E. M. Janssens, Sjef van der Linden, Annelies Boonen, Knowledge, illness perceptions and stated clinical practice behaviour in management of gout: a mixed methods study in general practice, Clinical Rheumatology, 2016,

    CrossRef

  31. 31
    Paul P. Doghramji, Steve Fermer, Robert Wood, Robert Morlock, Scott Baumgartner, Management of gout in the real world: current practice versus guideline recommendations, Postgraduate Medicine, 2016, 128, 1, 106

    CrossRef

  32. 32
    Robert T. Keenan, Naomi Schlesinger, New and Pipeline Drugs for Gout, Current Rheumatology Reports, 2016, 18, 6

    CrossRef

  33. 33
    Frédéric Lioté, New therapeutic approach to hyperuricemia and gout in the light of recommendations, Joint Bone Spine, 2016,

    CrossRef

  34. 34
    Thomas Bardin, Stéphane Bouée, Pierre Clerson, Gérard Chalès, René-Marc Flipo, Frédéric Lioté, Vincent Perez, Thierry Poiraud, Thierry Schaeverbeke, Pascal Richette, Prevalence of Gout in the Adult Population of France, Arthritis Care & Research, 2016, 68, 2
  35. 35
    Na Lu, Sharan K. Rai, Robert Terkeltaub, Seoyoung C. Kim, Mariano E. Menendez, Hyon K. Choi, Racial Disparities in the Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis as Urate-Lowering Drug Adverse Events in the US, Seminars in Arthritis and Rheumatism, 2016,

    CrossRef

  36. 36
    Xing Kang, Rong Chen, Min Han, Zhengbin Liu, Jinhui Liu, Penggao Dai, Chao Chen, Huijuan Wang, Rapid and reliable genotyping ofHLA-B*58:01in four Chinese populations using a single-tube duplex real-time PCR assay, Pharmacogenomics, 2016, 17, 1, 47

    CrossRef

  37. 37
    Nicola Dalbeth, Gregory D. Gamble, Anne Horne, Ian R. Reid, Relationship Between Changes in Serum Urate and Bone Mineral Density During Treatment with Thiazide Diuretics: Secondary Analysis from a Randomized Controlled Trial, Calcified Tissue International, 2016, 98, 5, 474

    CrossRef

  38. 38
    S. O. Ahn, S. Ohtomo, J. Kiyokawa, T. Nakagawa, M. Yamane, K. J. Lee, K. H. Kim, B. H. Kim, J. Tanaka, Y. Kawabe, N. Horiba, Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone, Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 1, 157

    CrossRef

  39. 39
    Haiyan Chen, Shucong Zheng, Yuankai Wang, Huiqing Zhu, Qiong Liu, Yu Xue, Jianhua Qiu, Hejian Zou, Xiaoxia Zhu, The effect of resveratrol on the recurrent attacks of gouty arthritis, Clinical Rheumatology, 2016, 35, 5, 1189

    CrossRef

  40. 40
    Haiyan Chen, Shucong Zheng, Yuankai Wang, Huiqing Zhu, Qiong Liu, Yu Xue, Jianhua Qiu, Hejian Zou, Xiaoxia Zhu, The effect of resveratrol on the recurrent attacks of gouty arthritis, Clinical Rheumatology, 2016, 35, 5, 1189

    CrossRef

  41. 41
    Isaac R. Kasper, Matthew D. Juriga, John M. Giurini, Robert H. Shmerling, Treatment of tophaceous gout: When medication is not enough, Seminars in Arthritis and Rheumatism, 2016,

    CrossRef

  42. 42
    David Hyndman, Sha Liu, Jeffrey N. Miner, Urate Handling in the Human Body, Current Rheumatology Reports, 2016, 18, 6

    CrossRef

  43. 43
    Giuseppe Maiolino, Elisa Pagnin, Mario Plebani, Paul A. Davis, Lorenzo A. Calò, Uric acid and cardiovascular-renal disease risk. Insights from a human model opposite to hypertension, International Journal of Cardiology, 2016, 212, 18

    CrossRef

  44. 44
    Shaoyong Xu, Xiangyang Liu, Jie Ming, Shenren Chen, Yangang Wang, Xiumei Liu, Hong Liu, Yongde Peng, Jianqin Wang, Jinying Lin, Haiwang Ji, Bin Liu, Ying Lu, Peng Liu, Yonghong Zhang, Qiuhe Ji, A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia, International Journal of Rheumatic Diseases, 2015, 18, 6
  45. 45
    Sergio García-Méndez, Carolina Bustos Rivera-Bahena, José Luis Montiel-Hernández, Daniel Xibillé-Friedmann, Everardo Álvarez-Hernández, Ingris Peláez-Ballestas, Rubén Burgos-Vargas, Janitzia Vázquez-Mellado, A Prospective Follow-Up of Adipocytokines in Cohort Patients With Gout, Medicine, 2015, 94, 26, e935

    CrossRef

  46. 46
    Aylin Altan, Aki Shiozawa, Tim Bancroft, Jasvinder A. Singh, A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database, JCR: Journal of Clinical Rheumatology, 2015, 21, 8, 411

    CrossRef

  47. 47
    Fernando Perez-Ruiz, Nicola Dalbeth, Tomas Bardin, A Review of Uric Acid, Crystal Deposition Disease, and Gout, Advances in Therapy, 2015, 32, 1, 31

    CrossRef

  48. 48
    Gemma E. Shields, Stephen M. Beard, A Systematic Review of the Economic and Humanistic Burden of Gout, PharmacoEconomics, 2015, 33, 10, 1029

    CrossRef

  49. 49
    Emily Black, Ingrid Sketris, Chris Skedgel, Erica MacLean, John G Hanly, Adherence to Guidelines and the Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions Criteria for Colchicine Dosing for Gout Treatment in Beneficiaries of the Nova Scotia Seniors’ Pharmacare Program, Clinical Therapeutics, 2015, 37, 10, 2339

    CrossRef

  50. 50
    Philip C Robinson, Nicola Dalbeth, Advances in pharmacotherapy for the treatment of gout, Expert Opinion on Pharmacotherapy, 2015, 16, 4, 533

    CrossRef

  51. 51
    S. Mantarro, A. Capogrosso-Sansone, M. Tuccori, C. Blandizzi, S. Montagnani, I. Convertino, L. Antonioli, M. Fornai, I. Cricelli, S. Pecchioli, C. Cricelli, F. Lapi, Allopurinol adherence among patients with gout: an Italian general practice database study, International Journal of Clinical Practice, 2015, 69, 7
  52. 52
    Hong Ki Min, Boin Lee, Seung-Ki Kwok, Ji Hyeon Ju, Wan-Uk Kim, Young Min Park, Sung-Hwan Park, Allopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics and clinical outcomes, The Korean Journal of Internal Medicine, 2015, 30, 4, 521

    CrossRef

  53. 53
    Lisa K. Stamp, Richard O. Day, James Yun, Allopurinol hypersensitivity: investigating the cause and minimizing the risk, Nature Reviews Rheumatology, 2015, 12, 4, 235

    CrossRef

  54. 54
    Michael A. Becker, David Fitz-Patrick, Hyon K. Choi, Nicola Dalbeth, Chris Storgard, Matt Cravets, Scott Baumgartner, An open-label, 6-month study of allopurinol safety in gout: The LASSO study, Seminars in Arthritis and Rheumatism, 2015, 45, 2, 174

    CrossRef

  55. 55
    Sara Ciarla, Paolo Giorgini, Manuela Struglia, Rinaldo Striuli, Stefano Necozione, Giovambattista Desideri, Giuliana Properzi, Claudio Ferri, Associations between low levels of serum uric acid and cardiometabolic parameters, Archives of Physiology and Biochemistry, 2015, 121, 4, 139

    CrossRef

  56. 56
    Hiroko Murata, Satomi Oshima, Suguru Torii, Motoko Taguchi, Mitsuru Higuchi, Characteristics of body composition and cardiometabolic risk of Japanese male heavyweight Judo athletes, Journal of Physiological Anthropology, 2015, 35, 1

    CrossRef

  57. 57
    Jasvinder A Singh, Kasem S Akhras, Aki Shiozawa, Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort, Arthritis Research & Therapy, 2015, 17, 1

    CrossRef

  58. 58
    Xin Feng, Yao Li, Wei Gao, Conséquences du moment de l’introduction d’un traitement hypo-uricémiant chez des patients souffrant d’un accès de goutte : étude rétrospective, Revue du Rhumatisme, 2015, 82, 6, 386

    CrossRef

  59. 59
    Dong-Jin Park, Ji-Hyoun Kang, Jeong-Won Lee, Kyung-Eun Lee, Lihui Wen, Tae-Jong Kim, Yong-Wook Park, Sung-Hwan Park, Shin-Seok Lee, Cost-Effectiveness Analysis of HLA–B5801 Genotyping in the Treatment of Gout Patients With Chronic Renal Insufficiency in Korea, Arthritis Care & Research, 2015, 67, 2
  60. 60
    Di Dong, Wei-Chuen Tan-Koi, Gim Gee Teng, Eric Finkelstein, Cynthia Sung, Cost–effectiveness analysis of genotyping forHLA-B*5801and an enhanced safety program in gout patients starting allopurinol in Singapore, Pharmacogenomics, 2015, 16, 16, 1781

    CrossRef

  61. 61
    Samya Mohammad, Stephanie L. Giattino, Robert T. Keenan, Current and Emerging Therapies for Gout, Current Treatment Options in Rheumatology, 2015, 1, 2, 143

    CrossRef

  62. 62
    J. Sautner, Diagnose und Therapiestandard der Gicht in Österreich, rheuma plus, 2015, 14, 1, 18

    CrossRef

  63. 63
    Erica M. Hill, Karen Sky, Michelle Sit, Angelique Collamer, Jay Higgs, Does Starting Allopurinol Prolong Acute Treated Gout? A Randomized Clinical Trial, JCR Journal of Clinical Rheumatology, 2015, 21, 3, 120

    CrossRef

  64. You have free access to this content64
    Ying Sun, Huiyong Chen, Zhuojun Zhang, Lili Ma, Jianjun Zhou, Yi Zhou, Yuqin Ding, Xuejuan Jin, Lindi Jiang, Dual-energy computed tomography for monitoring the effect of urate-lowering therapy in gouty arthritis, International Journal of Rheumatic Diseases, 2015, 18, 8
  65. 65
    Seoyoung C. Kim, Sebastian Schneeweiss, Niteesh Choudhry, Jun Liu, Robert J. Glynn, Daniel H. Solomon, Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: A Cohort Study, The American Journal of Medicine, 2015, 128, 6, 653.e7

    CrossRef

  66. 66
    Mariano Andrés, Francisca Sivera, Eliseo Pascual, Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: Ascertaining the Efficacy of Treatment Matters, The American Journal of Medicine, 2015, 128, 9, e41

    CrossRef

  67. 67
    Bettina Engel, Klaus Weckbecker, Markus Bleckwenn, Ein Fall für den „Beulendoktor“, MMW - Fortschritte der Medizin, 2015, 157, 6, 59

    CrossRef

  68. 68
    Anne Brinster, Xavier Guillot, Sophie Borot, Clément Prati, Daniel Wendling, Évolution du profil des hospitalisations pour goutte dans un service de rhumatologie, Revue du Rhumatisme, 2015, 82, 4, 272

    CrossRef

  69. 69
    Puja P. Khanna, John FitzGerald, Evolution of management of gout, Current Opinion in Rheumatology, 2015, 27, 2, 139

    CrossRef

  70. 70
    Anne Brinster, Xavier Guillot, Sophie Borot, Clément Prati, Daniel Wendling, Evolution of the profile of patients hospitalized for gout in a tertiary rheumatology unit, Joint Bone Spine, 2015, 82, 4, 296

    CrossRef

  71. 71
    Mary Barna Bridgeman, Benjamin Chavez, Febuxostat for the treatment of gout, Expert Opinion on Pharmacotherapy, 2015, 1

    CrossRef

  72. 72
    James E. Frampton, Febuxostat: A Review of Its Use in the Treatment of Hyperuricaemia in Patients with Gout, Drugs, 2015, 75, 4, 427

    CrossRef

  73. 73
    Robert Jackson, Aki Shiozawa, Erin K Buysman, Aylin Altan, Stephanie Korrer, Hyon Choi, Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis, BMJ Open, 2015, 5, 6, e007214

    CrossRef

  74. 74
    Gim Gee Teng, An Pan, Jian-Min Yuan, Woon-Puay Koh, Food Sources of Protein and Risk of Incident Gout in the Singapore Chinese Health Study, Arthritis & Rheumatology, 2015, 67, 7
  75. 75
    Samantha Jarjour, Mathieu Barrette, Valérie Normand, Jean Lucien Rouleau, Marie-Pierre Dubé, Simon de Denus, Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review, Pharmacogenomics, 2015, 16, 7, 755

    CrossRef

  76. 76
    CC Wen, SW Yee, X Liang, TJ Hoffmann, MN Kvale, Y Banda, E Jorgenson, C Schaefer, N Risch, KM Giacomini, Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response, Clinical Pharmacology & Therapeutics, 2015, 97, 5
  77. 77
    Matthew J Roughley, John Belcher, Christian D Mallen, Edward Roddy, Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies, Arthritis Research & Therapy, 2015, 17, 1

    CrossRef

  78. 78
    Stephen P. Juraschek, Lara C. Kovell, Edgar R. Miller, Allan C. Gelber, Gout, Urate-Lowering Therapy, and Uric Acid Levels Among Adults in the United States, Arthritis Care & Research, 2015, 67, 4
  79. 79
    Sneha Pai, Ashraf Raslan, Naomi Schlesinger, Gout: Update on Current Therapeutics, Current Treatment Options in Rheumatology, 2015, 1, 2, 131

    CrossRef

  80. 80
    Nicola Dalbeth, Lisa K. Stamp, Gout: Why compare the effectiveness of suboptimal gout management?, Nature Reviews Rheumatology, 2015, 11, 9, 506

    CrossRef

  81. 81
    Mihra S. Taljanovic, David M. Melville, Lana H. Gimber, Luke R. Scalcione, Margaret D. Miller, C. Kent Kwoh, Andrea S. Klauser, High-Resolution US of Rheumatologic Diseases, RadioGraphics, 2015, 35, 7, 2026

    CrossRef

  82. 82
    Peter M. Sullivan, Asch William, Eric M. Tichy, Hyperuricemia and gout in solid-organ transplant: update in pharmacological management, Progress in Transplantation, 2015, 25, 3, 263

    CrossRef

  83. 83
    L. Sellin, J.T. Kielstein, K. de Groot, Hyperurikämie – mehr als Gicht, Zeitschrift für Rheumatologie, 2015, 74, 4, 322

    CrossRef

  84. 84
    Annalina Avram, Cátia Duarte, Maria José Santos, Charalampos Papagoras, Konstantinos Ritis, Roberto Scarpioni, Wolfgang A. Schmidt, Panagiotis Skendros, Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases, Joint Bone Spine, 2015, 82, eS17

    CrossRef

  85. 85
    Pascal Richette, Aline Frazier, Thomas Bardin, Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout, Current Opinion in Rheumatology, 2015, 27, 2, 170

    CrossRef

  86. 86
    L. E. Clarson, S. L. Hider, J. Belcher, C. Heneghan, E. Roddy, C. D. Mallen, Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink, Annals of the Rheumatic Diseases, 2015, 74, 4, 642

    CrossRef

  87. 87
    Hania Shahid, Jasvinder A Singh, Investigational drugs for hyperuricemia, Expert Opinion on Investigational Drugs, 2015, 24, 8, 1013

    CrossRef

  88. 88
    Gerald Levy, T. Craig Cheetham, Is It Time to Start Treating Asymptomatic Hyperuricemia?, American Journal of Kidney Diseases, 2015, 66, 6, 933

    CrossRef

  89. 89
    Gail S. Kerr, John S. Richards, Carl A. Nunziato, Olga V. Patterson, Scott L. DuVall, Mireille Aujero, David Maron, Richard Amdur, Measuring Physician Adherence With Gout Quality Indicators: A Role for Natural Language Processing, Arthritis Care & Research, 2015, 67, 2
  90. 90
    Giuseppe Lippi, Camilla Mattiuzzi, Gianfranco Cervellin, Meat consumption and gout: Friend, foe or neither?, Rheumatology International, 2015, 35, 8, 1443

    CrossRef

  91. 91
    Takeshi Nishino, Ken Okamoto, Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout, JBIC Journal of Biological Inorganic Chemistry, 2015, 20, 2, 195

    CrossRef

  92. 92
    Logan Carr, Sebastian Brooke, John Ingraham, Medically managed gout precipitating acute carpal tunnel syndrome, HAND, 2015, 10, 3, 574

    CrossRef

  93. 93
    Nicola Dalbeth, Ruth Topless, Tanya Flynn, Murray Cadzow, Mark J Bolland, Tony R Merriman, Mendelian Randomization Analysis to Examine for a Causal Effect of Urate on Bone Mineral Density, Journal of Bone and Mineral Research, 2015, 30, 6
  94. 94
    O. Godin, M. Leboyer, A. Gaman, B. Aouizerate, F. Berna, L. Brunel, D. Capdevielle, I. Chereau, J.M. Dorey, C. Dubertret, J. Dubreucq, C. Faget, F. Gabayet, Y. Le Strat, P.M. Llorca, D. Misdrahi, R. Rey, R. Richieri, C. Passerieux, A. Schandrin, F. Schürhoff, M. Urbach, P. Vidalhet, N. Girerd, G. Fond, Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort, Schizophrenia Research, 2015, 168, 1-2, 388

    CrossRef

  95. 95
    Cesar Diaz-Torné, Nuria Perez-Herrero, Fernando Perez-Ruiz, New medications in development for the treatment of hyperuricemia of gout, Current Opinion in Rheumatology, 2015, 27, 2, 164

    CrossRef

  96. 96
    J. Sautner, G. Eichbauer-Sturm, J. Gruber, R. Puchner, P. Spellitz, C. Strehblow, J. Zwerina, G. Eberl, Österreichische Ernährungs- und Lebensstilempfehlungen bei Gicht und Hyperurikämie, rheuma plus, 2015, 14, 4, 109

    CrossRef

  97. 97
    J. Sautner, G. Eichbauer-Sturm, J. Gruber, R. Puchner, P. Spellitz, C. Strehblow, J. Zwerina, G. Eberl, Österreichische Ernährungs- und Lebensstilempfehlungen bei Gicht und Hyperurikämie, Zeitschrift für Rheumatologie, 2015, 74, 7, 631

    CrossRef

  98. 98
    Navine Nasser-Ghodsi, Leslie R. Harrold, Overcoming adherence issues and other barriers to optimal care in gout, Current Opinion in Rheumatology, 2015, 27, 2, 134

    CrossRef

  99. 99
    Rebecca L Roberts, Lisa K Stamp, Pharmacogenetic considerations in the treatment of gout, Pharmacogenomics, 2015, 16, 6, 619

    CrossRef

  100. 100
    Wei-Chuen Tan-Koi, Ritika Kapoor, Yik-Ying Teo, Pharmacogenetics through a public health lens, Pharmacogenetics and Genomics, 2015, 25, 10, 518

    CrossRef

  101. 101
    Julia M. Barbarino, Deanna L. Kroetz, Teri E. Klein, Russ B. Altman, PharmGKB summary, Pharmacogenetics and Genomics, 2015, 25, 4, 205

    CrossRef

  102. 102
    Hamid Mustafa, Pitfalls in management of acute gouty attack, a qualitative research conducted in Makah Region – Saudi Arabia, Alexandria Journal of Medicine, 2015, 51, 2, 121

    CrossRef

  103. 103
    Christopher Banse, Patrice Fardellone, Julien Paccou, Prévalence des traitements hypouricémiants chez des patients hospitalisés en rhumatologie et évaluation du respect des recommandations de l’ACR 2012, Revue du Rhumatisme, 2015, 82, 1, 60

    CrossRef

  104. 104
    Minrui Li, Shenghong Zhang, Yanqin Wu, Junzhao Ye, Xu Cao, Jie Liu, Yanhong Sun, Bihui Zhong, Prevalence of Insulin Resistance in Subjects with Nonalcoholic Fatty Liver Disease and Its Predictors in a Chinese Population, Digestive Diseases and Sciences, 2015, 60, 7, 2170

    CrossRef

  105. 105
    Aaron S. Kesselheim, Jessica M. Franklin, Seoyoung C. Kim, John D. Seeger, Daniel H. Solomon, Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population, Journal of General Internal Medicine, 2015, 30, 11, 1633

    CrossRef

  106. 106
    Thomas Bardin, Gérard Chalès, Tristan Pascart, René-Marc Flipo, Hang Korng Ea, Jean-Claude Roujeau, Aurélie Delayen, Pierre Clerson, Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment, Joint Bone Spine, 2015,

    CrossRef

  107. 107
    L. Pasina, S. A. M. Urru, P. Minghetti, C. Giua, Role of Community Pharmacies for the Detection of Potentially Inappropriate Xanthine Oxidase Inhibitor Prescriptions, Drugs - Real World Outcomes, 2015, 2, 1, 81

    CrossRef

  108. 108
    Riccardo G Borroni, Role of dermatology in pharmacogenomics: drug-induced skin injury, Pharmacogenomics, 2015, 16, 4, 401

    CrossRef

  109. 109
    Kentaro Tanaka, Shigeko Hara, Masakazu Hattori, Ken Sakai, Yukiko Onishi, Yoko Yoshida, Shoji Kawazu, Akifumi Kushiyama, Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes, Journal of Diabetes Investigation, 2015, 6, 1
  110. 110
    Christopher E. Ekpenyong, Nyebuk Daniel, Roles of diets and dietary factors in the pathogenesis, management and prevention of abnormal serum uric acid levels, PharmaNutrition, 2015, 3, 2, 29

    CrossRef

  111. You have free access to this content111
    Rebecca Grainger, Andrew A. Harrison, Rules of engagement: turning recommendations into results in the diagnosis and management of gout, International Journal of Rheumatic Diseases, 2015, 18, 3
  112. 112
    Claudio Borghi, Enrico Agabiti Rosei, Thomas Bardin, Jesse Dawson, Anna Dominiczak, Jan T. Kielstein, Athanasios J. Manolis, Fernando Perez-Ruiz, Giuseppe Mancia, Serum uric acid and the risk of cardiovascular and renal disease, Journal of Hypertension, 2015, 33, 9, 1729

    CrossRef

  113. 113
    Xin Feng, Yao Li, Wei Gao, Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research, Joint Bone Spine, 2015, 82, 6, 428

    CrossRef

  114. You have free access to this content114
    Patapong Towiwat, Zhan-Guo Li, The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout, International Journal of Rheumatic Diseases, 2015, 18, 5
  115. 115
    Ashika Chhana, Nicola Dalbeth, The Gouty Tophus: a Review, Current Rheumatology Reports, 2015, 17, 3

    CrossRef

  116. 116
    Eric Wise, Puja P. Khanna, The impact of gout guidelines, Current Opinion in Rheumatology, 2015, 27, 3, 225

    CrossRef

  117. 117
    G. Desideri, J.G. Puig, P. Richette, The management of hyperuricemia with urate deposition, Current Medical Research and Opinion, 2015, 31, sup2, 27

    CrossRef

  118. 118
    Eo Chin Kim, Jong Sung Kim, Won Chul Uh, Soo Young Choi, Sun Kyung Lee, Bog Seon Jeong, The Relationship between Uric Acid and Homocysteine Levels based on Alcohol-related Facial Flushing, Korean Journal of Health Promotion, 2015, 15, 3, 91

    CrossRef

  119. 119
    Scott J. Saccomano, Lucille R. Ferrara, Treatment and prevention of gout, The Nurse Practitioner, 2015, 40, 8, 24

    CrossRef

  120. 120
    Sébastien Ottaviani, Ghislaine Gill, Aurore Aubrun, Elisabeth Palazzo, Olivier Meyer, Philippe Dieudé, Ultrasound in gout: A useful tool for following urate-lowering therapy, Joint Bone Spine, 2015, 82, 1, 42

    CrossRef

  121. 121
    R. C. Hmar, D. R. W. Kannangara, S. N. Ramasamy, M. T. Baysari, K. M. Williams, R. O. Day, Understanding and improving the use of allopurinol in a teaching hospital, Internal Medicine Journal, 2015, 45, 4
  122. 122
    GM Mody, Update on hyperuricaemia and gout with evidence based management guidelines, South African Family Practice, 2015, 57, 4, 267

    CrossRef

  123. 123
    Tahir Kanji, Mandark Gandhi, Catherine M Clase, Robert Yang, Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis, BMC Nephrology, 2015, 16, 1

    CrossRef

  124. 124
    Keith Rome, Mike Frecklington, Management of Chronic Conditions in the Foot and Lower Leg, 2015,

    CrossRef

  125. 125
    A. J. Teichtahl, L. Clemens, M. Nikpour, E. Romas, A prospective study of acute inpatient gout diagnoses and management in a tertiary hospital: the determinants and outcome of a rheumatology consultation, Internal Medicine Journal, 2014, 44, 11
  126. 126
    Hind Hatoum, Dinesh Khanna, Swu–Jane Lin, Kasem S. Akhras, Aki Shiozawa, Puja Khanna, Achieving Serum Urate Goal: A Comparative Effectiveness Study between Allopurinol and Febuxostat, Postgraduate Medicine, 2014, 126, 2, 65

    CrossRef

  127. 127
    Tuhina Neogi, Clara Chen, Jingbo Niu, Christine Chaisson, David J. Hunter, Yuqing Zhang, Alcohol Quantity and Type on Risk of Recurrent Gout Attacks: An Internet-based Case-crossover Study, The American Journal of Medicine, 2014, 127, 4, 311

    CrossRef

  128. 128
    Xinfang Huang, Hui Du, Jieruo Gu, Dongbao Zhao, Lindi Jiang, Xinfu Li, Xiaoxia Zuo, Yi Liu, Zhanguo Li, Xiangpei Li, Ping Zhu, Juan Li, Zhiyi Zhang, Anbin Huang, Yuanchao Zhang, Chunde Bao, An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia, International Journal of Rheumatic Diseases, 2014, 17, 6
  129. 129
    George Nuki, An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of Gout, Current Opinion in Rheumatology, 2014, 26, 2, 152

    CrossRef

  130. 130
    A.-K. Tausche, M. Christoph, M. Forkmann, U. Richter, S. Kopprasch, C. Bielitz, M. Aringer, C. Wunderlich, As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout, Rheumatology International, 2014, 34, 1, 101

    CrossRef

  131. 131
    H. K. Choi, Y. Zhang, Bariatric surgery as urate-lowering therapy in severe obesity, Annals of the Rheumatic Diseases, 2014, 73, 5, 791

    CrossRef

  132. 132
    Chapter 5. Treatment with antihypertensive drugs, Hypertension Research, 2014, 37, 4, 291

    CrossRef

  133. 133
    Fernando Perez-Ruiz, Edwin Castillo, Sandra P. Chinchilla, Ana M. Herrero-Beites, Clinical Manifestations and Diagnosis of Gout, Rheumatic Disease Clinics of North America, 2014, 40, 2, 193

    CrossRef

  134. 134
    Akiyoshi Nakayama, Hirotaka Matsuo, Hirofumi Nakaoka, Takahiro Nakamura, Hiroshi Nakashima, Yuzo Takada, Yuji Oikawa, Tappei Takada, Masayuki Sakiyama, Seiko Shimizu, Yusuke Kawamura, Toshinori Chiba, Junko Abe, Kenji Wakai, Sayo Kawai, Rieko Okada, Takashi Tamura, Yuka Shichijo, Airi Akashi, Hiroshi Suzuki, Tatsuo Hosoya, Yutaka Sakurai, Kimiyoshi Ichida, Nariyoshi Shinomiya, Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors, Scientific Reports, 2014, 4,

    CrossRef

  135. You have free access to this content135
    Liza Wilson, Kavita V. Nair, Joseph J. Saseen, Comparison of New-Onset Gout in Adults Prescribed Chlorthalidone vs Hydrochlorothiazide for Hypertension, The Journal of Clinical Hypertension, 2014, 16, 12
  136. 136
    Thomas Bardin, Pascal Richette, Definition of hyperuricemia and gouty conditions, Current Opinion in Rheumatology, 2014, 26, 2, 186

    CrossRef

  137. 137
    J. Sautner, Diagnose und Therapiestandard der Gicht in Österreich, Zeitschrift für Rheumatologie, 2014, 73, 9, 836

    CrossRef

  138. 138
    Sébastien Ottaviani, Ghislaine Gill, Aurore Aubrun, Elisabeth Palazzo, Olivier Meyer, Philippe Dieudé, Échographie dans la goutte : un outil utile dans le suivi du traitement hypouricémiant, Revue du Rhumatisme, 2014, 81, 6, 491

    CrossRef

  139. 139
    Tatsuo Hosoya, Iwao Ohno, Shinsuke Nomura, Ichiro Hisatome, Shunya Uchida, Shin Fujimori, Tetsuya Yamamoto, Shigeko Hara, Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout, Clinical and Experimental Nephrology, 2014, 18, 6, 876

    CrossRef

  140. 140
    Rebeca Bailén, Nicolás M. González Senac, Mónica M. López, M. Luisa Llena, Marta Migoya, M. Teresa Rodríguez, Eugenio de Miguel, Rosa J. Torres, Juan G. Puig, Efficacy and Safety of a Urate Lowering Regimen in Primary Gout, Nucleosides, Nucleotides and Nucleic Acids, 2014, 33, 4-6, 174

    CrossRef

  141. 141
    N. Lawrence Edwards, Alexander So, Emerging Therapies for Gout, Rheumatic Disease Clinics of North America, 2014, 40, 2, 375

    CrossRef

  142. 142
    Tristan Pascart, Emmanuel Biver, Cécile Wibaux, Audrey Juillard, Bernard Cortet, René-Marc Flipo, Étude des hospitalisations pour goutte dans un service de rhumatologie entre 2000 et 2010 – Analyse rétrospective de 114 observations, Revue du Rhumatisme, 2014, 81, 1, 35

    CrossRef

  143. 143
    Jasvinder A Singh, Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study, Arthritis Research & Therapy, 2014, 16, 2, R82

    CrossRef

  144. 144
    Yukinao Sakai, Tomoyuki Otsuka, Dai Ohno, Tsuneo Murasawa, Naoki Sato, Shuichi Tsuruoka, Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease, Renal Failure, 2014, 36, 2, 225

    CrossRef

  145. 145
    Harmanjot K Grewal, Joseph R Martinez, Luis R Espinoza, Febuxostat: drug review and update, Expert Opinion on Drug Metabolism & Toxicology, 2014, 10, 5, 747

    CrossRef

  146. 146
    Mirko Scarsi, Carla Bosio, Silvia Coccoli, Amilcare Barucco, Giovanna Tavelli, Paolo Airò, Flow cytometry test to screen for HLA-B*58:01-associated allopurinol hypersensitivity, Clinical Rheumatology, 2014, 33, 6, 873

    CrossRef

  147. 147
    Tristan Pascart, Erwan Oehler, René-Marc Flipo, Gout in French Polynesia: A survey of common practices, Joint Bone Spine, 2014, 81, 4, 374

    CrossRef

  148. 148
    Bonifacio Álvarez-Lario, José L. Alonso-Valdivielso, Gout treatment: when a tablet is not enough, Nature Reviews Rheumatology, 2014, 10, 3, 193

    CrossRef

  149. 149
    Philip C. Robinson, Simon Horsburgh, Gout: Joints and beyond, epidemiology, clinical features, treatment and co-morbidities, Maturitas, 2014, 78, 4, 245

    CrossRef

  150. 150
    Monika A Reuss-Borst, Cornelia A Pape, Anne K Tausche, Hidden gout- Ultrasound findings in patients with musculo-skeletal problems and hyperuricemia, SpringerPlus, 2014, 3, 1, 592

    CrossRef

  151. 151
    Jisuk Bae, Byung-Yeol Chun, Pil Sook Park, Bo Youl Choi, Mi Kyung Kim, Min-Ho Shin, Young-Hoon Lee, Dong Hoon Shin, Seong-Kyu Kim, Higher consumption of sugar-sweetened soft drinks increases the risk of hyperuricemia in Korean population: The Korean Multi-Rural Communities Cohort Study, Seminars in Arthritis and Rheumatism, 2014, 43, 5, 654

    CrossRef

  152. 152
    Chi-Yuan Cheng, Shih-Chi Su, Chi-Hua Chen, Wei-Li Chen, Shin-Tarng Deng, Wen-Hung Chung, HLA Associations and Clinical Implications in T-Cell Mediated Drug Hypersensitivity Reactions: An Updated Review, Journal of Immunology Research, 2014, 2014, 1

    CrossRef

  153. 153
    N. Dalbeth, P. Chen, M. White, G. D. Gamble, C. Barratt-Boyes, P. J. Gow, B. Orr-Walker, Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study, Annals of the Rheumatic Diseases, 2014, 73, 5, 797

    CrossRef

  154. 154
    Lisa K. Stamp, Tony R. Merriman, Murray L. Barclay, Jasvinder A. Singh, Rebecca L. Roberts, Daniel F.B. Wright, Nicola Dalbeth, Impaired response or insufficient dosage?—Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout, Seminars in Arthritis and Rheumatism, 2014, 44, 2, 170

    CrossRef

  155. 155
    L. Pasina, A. L. Brucato, C. D. Djade, P. Di Corato, S. Ghidoni, M. Tettamanti, C. Franchi, F. Salerno, S. Corrao, A. Marengoni, M. Marcucci, P. M. Mannucci, A. Nobili, Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry, European Journal of Clinical Pharmacology, 2014, 70, 12, 1495

    CrossRef

  156. 156
    Tristan Pascart, Erwan Oehler, René-Marc Flipo, La goutte en Polynésie française : enquête sur la pratique quotidienne, Revue du Rhumatisme, 2014, 81, 4, 352

    CrossRef

  157. 157
    Yashaar Chaichian, Saima Chohan, Michael A. Becker, Long-Term Management of Gout, Rheumatic Disease Clinics of North America, 2014, 40, 2, 357

    CrossRef

  158. 158
    Eric W Orlowsky, Thomas V Stabler, Eulàlia Montell, Josep Vergés, Virginia Kraus, Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis?, BMC Musculoskeletal Disorders, 2014, 15, 1, 318

    CrossRef

  159. 159
    F. Sivera, M. Andres, L. Carmona, A. S. R. Kydd, J. Moi, R. Seth, M. Sriranganathan, C. van Durme, I. van Echteld, O. Vinik, M. D. Wechalekar, D. Aletaha, C. Bombardier, R. Buchbinder, C. J. Edwards, R. B. Landewe, J. W. Bijlsma, J. C. Branco, R. Burgos-Vargas, A. I. Catrina, D. Elewaut, A. J. L. Ferrari, P. Kiely, B. F. Leeb, C. Montecucco, U. Muller-Ladner, M. Ostergaard, J. Zochling, L. Falzon, D. M. van der Heijde, Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative, Annals of the Rheumatic Diseases, 2014, 73, 2, 328

    CrossRef

  160. 160
    Frances Rees, Michelle Hui, Michael Doherty, Optimizing current treatment of gout, Nature Reviews Rheumatology, 2014, 10, 5, 271

    CrossRef

  161. 161
    Judith Sautner, Johann Gruber, Manfred Herold, Jochen Zwerina, Burkhard F. Leeb, Österreichische 3e-Empfehlungen zu Diagnose und Management von Gicht 2013, Wiener klinische Wochenschrift, 2014, 126, 3-4, 79

    CrossRef

  162. 162
    Pascal Richette, Aline Frazier, Thomas Bardin, Pharmacokinetics considerations for gout treatments, Expert Opinion on Drug Metabolism & Toxicology, 2014, 10, 7, 949

    CrossRef

  163. 163
    Ellen M. McDonagh, Caroline F. Thorn, John T. Callaghan, Russ B. Altman, Teri E. Klein, PharmGKB summary, Pharmacogenetics and Genomics, 2014, 24, 9, 464

    CrossRef

  164. 164
    Gary. M. Oderda, Aki Shiozawa, Michael Walsh, Kyle Hess, Diana. I. Brixner, Michael Feehan, Kasem Akhras, Physician Adherence to ACR Gout Treatment Guidelines: Perception Versus Practice, Postgraduate Medicine, 2014, 126, 3, 257

    CrossRef

  165. 165
    Jérôme Gillard, Marie Pierre Perret, Julie Lacroix, Claire Berthod, Catherine Bourgon, Gilles Leboube, Premier programme d’éducation thérapeutique du patient pour la goutte autorisé en France, Revue du Rhumatisme, 2014, 81, 5, 444

    CrossRef

  166. 166
    Christopher Banse, Patrice Fardellone, Julien Paccou, Prevalence of treatment of hyperuricemic in patients admitted to the Rheumatology ward and evaluation of compliance with the 2012 ACR Guidelines, Joint Bone Spine, 2014, 81, 5, 461

    CrossRef

  167. 167
    Kowoon Joo, Seong-Ryul Kwon, Mie-Jin Lim, Kyong-Hee Jung, Hoyeon Joo, Won Park, Prevention of Comorbidity and Acute Attack of Gout by Uric Acid Lowering Therapy, Journal of Korean Medical Science, 2014, 29, 5, 657

    CrossRef

  168. 168
    A. Latourte, T. Bardin, P. Richette, Prophylaxis for acute gout flares after initiation of urate-lowering therapy, Rheumatology, 2014, 53, 11, 1920

    CrossRef

  169. 169
    Mariano Andrés, Francisca Sivera, Eliseo Pascual, Rapid crystal dissolution in gout: is it feasible and advisable?, International Journal of Clinical Rheumatology, 2014, 9, 4, 395

    CrossRef

  170. 170
    Alan D Lopez, Thomas N Williams, Adeera Levin, Marcello Tonelli, Jasvinder A Singh, Peter GJ Burney, Jürgen Rehm, Nora D Volkow, George Koob, Cleusa P Ferri, Remembering the forgotten non-communicable diseases, BMC Medicine, 2014, 12, 1

    CrossRef

  171. 171
    Fernando Perez-Ruiz, Ana Maria Herrero-Beites, Reply: Gout treatment—more tablets might be needed, Nature Reviews Rheumatology, 2014, 10, 3, 193

    CrossRef

  172. 172
    Lisa K. Stamp, Safety profile of anti-gout agents, Current Opinion in Rheumatology, 2014, 26, 2, 162

    CrossRef

  173. 173
    Lisa Stamp, Nicola Dalbeth, Screening for hyperuricaemia and gout: a perspective and research agenda, Nature Reviews Rheumatology, 2014, 10, 12, 752

    CrossRef

  174. 174
    Ashika Chhana, Nicola Dalbeth, Structural Joint Damage in Gout, Rheumatic Disease Clinics of North America, 2014, 40, 2, 291

    CrossRef

  175. 175
    Alexander Huppertz, Kay-Geert A. Hermann, Torsten Diekhoff, Moritz Wagner, Bernd Hamm, Wolfgang A. Schmidt, Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout, Rheumatology International, 2014, 34, 6, 763

    CrossRef

  176. 176
    Davide Grassi, Roberto Pontremoli, Raffaella Bocale, Claudio Ferri, Giovambattista Desideri, Therapeutic Approaches to Chronic Hyperuricemia and Gout, High Blood Pressure & Cardiovascular Prevention, 2014, 21, 4, 243

    CrossRef

  177. 177
    Tristan Pascart, Pascal Richette, René-Marc Flipo, Treatment of Nongout Joint Deposition Diseases: An Update, Arthritis, 2014, 2014, 1

    CrossRef

  178. 178
    Claudine G. Jennings, Isla S. Mackenzie, Rob Flynn, Ian Ford, George Nuki, Raffaele De Caterina, Philip L. Riches, Stuart H. Ralston, Thomas M. MacDonald, Up-titration of allopurinol in patients with gout, Seminars in Arthritis and Rheumatism, 2014, 44, 1, 25

    CrossRef

  179. 179
    Anne-Kathrin Tausche, Monika Reuss-Borst, Ute Koch, Urate Lowering Therapy with Febuxostat in Daily Practice—A Multicentre, Open-Label, Prospective Observational Study, International Journal of Rheumatology, 2014, 2014, 1

    CrossRef

  180. 180
    Lisa K. Stamp, Peter T. Chapman, Urate-Lowering Therapy: Current Options and Future Prospects for Elderly Patients with Gout, Drugs & Aging, 2014, 31, 11, 777

    CrossRef

  181. 181
    Monika Reuss-Borst, Was ist neu in der Diagnostik und Therapie der Gicht?, MMW - Fortschritte der Medizin, 2014, 156, 20, 58

    CrossRef

  182. 182
    Jean-Luc Girardet, Jeffrey N. Miner, 2014,

    CrossRef

  183. 183
    Labib I. Faruque, Arash Ehteshami-Afshar, Natasha Wiebe, Lisa Tjosvold, Joanne Homik, Marcello Tonelli, A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout, Seminars in Arthritis and Rheumatism, 2013, 43, 3, 367

    CrossRef

  184. 184
    S. Kobayashi, M. Ogura, T. Hosoya, Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease, Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 3
  185. 185
    J. Yun, J. Mattsson, K. Schnyder, S. Fontana, C. R. Largiadèr, W. J. Pichler, D. Yerly, Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response, Clinical & Experimental Allergy, 2013, 43, 11
  186. 186
    Diluk R. W. Kannangara, Sheena N. Ramasamy, John E. Ray, Graham Jones, Garry G. Graham, Kenneth M. Williams, Richard O. Day, An Audit of a Therapeutic Drug Monitoring Service for Allopurinol Therapy, Therapeutic Drug Monitoring, 2013, 35, 6, 863

    CrossRef

  187. 187
    R. Terkeltaub, Are cherries now ripe for use as a complementary therapeutic in gout? Appraisal of the state of evidence, Evidence-Based Medicine, 2013, 18, 6, 230

    CrossRef

  188. 188
    Tawatchai Paisansinsup, Matthew K. Breitenstein, John T. Schousboe, Association Between Adverse Reactions to Allopurinol and Exposures to High Maintenance Doses, Journal of Clinical Rheumatology, 2013, 19, 4, 180

    CrossRef

  189. 189
    Katherine A. Lyseng-Williamson, Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares, BioDrugs, 2013, 27, 4, 401

    CrossRef

  190. 190
    Seoyoung C. Kim, Bernhard M. W. Schmidt, Jessica M. Franklin, Jun Liu, Daniel H. Solomon, Sebastian Schneeweiss, Clinical and Health Care Use Characteristics of Patients Newly Starting Allopurinol, Febuxostat, and Colchicine for the Treatment of Gout, Arthritis Care & Research, 2013, 65, 12
  191. 191
    Jasvinder A. Singh, Crystal arthritis: Is HLAB genotyping the future of gout pharmacogenomics?, Nature Reviews Rheumatology, 2013, 9, 4, 200

    CrossRef

  192. 192
    M. A. Becker, P. A. MacDonald, B. J. Hunt, R. L. Jackson, Diabetes and gout: efficacy and safety of febuxostat and allopurinol, Diabetes, Obesity and Metabolism, 2013, 15, 11
  193. 193
    Hyo Jin Choi, Seung Kak Shin, Mi Ryung Seo, Hee Jung Ryu, Han Joo Baek, Duration of Prophylactic Therapy Affects the Frequency of Gout Flare, Journal of Rheumatic Diseases, 2013, 20, 1, 17

    CrossRef

  194. 194
    Cesar Diaz-Torne, Cesar Diaz-Lopez, Eficacia y efectividad de los tratamientos reductores de la uricemia, Seminarios de la Fundación Española de Reumatología, 2013, 14, 1, 8

    CrossRef

  195. 195
    Ronald L. George, Robert T. Keenan, Genetics of Hyperuricemia and Gout: Implications for the Present and Future, Current Rheumatology Reports, 2013, 15, 2

    CrossRef

  196. 196
    Dieter Schöffel, Gicht ist mehr als nur Podagra, Orthopädie & Rheuma, 2013, 16, 6, 30

    CrossRef

  197. 197
    Tristan Pascart, René-Marc Flipo, Gout: from international guidelines to current practice. Results from a physician questionnaire, Clinical Rheumatology, 2013, 32, 11, 1693

    CrossRef

  198. 198
    Robert Terkeltaub, Gout: Multinational gout guidelines: how do we move beyond 'déjà vu'?, Nature Reviews Rheumatology, 2013, 9, 10, 567

    CrossRef

  199. 199
    T. Bardin, G. Desideri, How to manage patients with gout, Current Medical Research and Opinion, 2013, 29, sup3, 17

    CrossRef

  200. 200
    Elizabeth Cottrell, Valerie Crabtree, John J Edwards, Edward Roddy, Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice, BMC Family Practice, 2013, 14, 1, 170

    CrossRef

  201. 201
    Jung-Soo Song, Jae-Bum Jun, Korean Guidelines for Tailored Management of Gout, Journal of Rheumatic Diseases, 2013, 20, 5, 280

    CrossRef

  202. 202
    Leslie Harrold, New developments in gout, Current Opinion in Rheumatology, 2013, 25, 3, 304

    CrossRef

  203. 203
    Adlene J Jebakumar, Prabhu D Udayakumar, Cynthia S Crowson, Eric L Matteson, Occurrence of gout in rheumatoid arthritis: it does happen! A population-based study, International Journal of Clinical Rheumatology, 2013, 8, 4, 433

    CrossRef

  204. 204
    Katherine A. Lyseng-Williamson, Pegloticase: a guide to its use in treatment-refractory chronic gout in the EU, Drugs & Therapy Perspectives, 2013, 29, 6, 155

    CrossRef

  205. 205
    Andrew Whelton, Patricia A. MacDonald, Solomon Chefo, Lhanoo Gunawardhana, Preservation of Renal Function during Gout Treatment with Febuxostat: A Quantitative Study, Postgraduate Medicine, 2013, 125, 1, 106

    CrossRef

  206. 206
    Qian-Hua Li, Lie Dai, Zhao-Xia Li, Hai-Jun Liu, Chan-Juan Zou, Xia Ou-Yang, Meng Lu, Ting Li, Yan-Hua Li, Yin-Qian Mo, H. Ralph Schumacher, Questionnaire survey evaluating disease-related knowledge for 149 primary gout patients and 184 doctors in South China, Clinical Rheumatology, 2013, 32, 11, 1633

    CrossRef

  207. 207
    Dinesh Khanna, Heather Gladue, Richard Channick, Lorinda Chung, Oliver Distler, Daniel E. Furst, Eric Hachulla, Marc Humbert, David Langleben, Stephen C. Mathai, Rajeev Saggar, Scott Visovatti, Nezam Altorok, Whitney Townsend, John FitzGerald, Vallerie V. McLaughlin, Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension, Arthritis & Rheumatism, 2013, 65, 12
  208. 208
    Nicola Dalbeth, Meaghan E House, Anne Horne, William J Taylor, Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout, BMC Musculoskeletal Disorders, 2013, 14, 1, 363

    CrossRef

  209. 209
    Carlos Mejía-Chew, Rosa J. Torres, Eugenio de Miguel, Juan G. Puig, Resolution of Massive Tophaceous Gout with Three Urate-lowering Drugs, The American Journal of Medicine, 2013, 126, 11, e9

    CrossRef

  210. 210
    Tran H. Tran, Jacqueline T. Pham, Hira Shafeeq, Kendra R. Manigault, Vibhuti Arya, Role of Interleukin-1 Inhibitors in the Management of Gout, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013, 33, 7
  211. 211
    Sung Won Lee, The Efficacy and Safety of Febuxostat in Korean Patients with Gout, Journal of Rheumatic Diseases, 2013, 20, 5, 277

    CrossRef

  212. 212
    David B. Mount, The kidney in hyperuricemia and gout, Current Opinion in Nephrology and Hypertension, 2013, 22, 2, 216

    CrossRef

  213. 213
    David Gustafsson, Robert Unwin, The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality, BMC Nephrology, 2013, 14, 1, 164

    CrossRef

  214. 214
    Garry G. Graham, Diluk R. W. Kannangara, Sophie L. Stocker, Ian Portek, Kevin D. Pile, Praveen L. Indraratna, Indira Datta, Kenneth M. Williams, Richard O. Day, Understanding the dose–response relationship of allopurinol: predicting the optimal dosage, British Journal of Clinical Pharmacology, 2013, 76, 6
  215. 215
    Richard O Day, Kenneth M Williams, Garry G Graham, Gout, 2013,

    CrossRef

  216. 216
    Puja P Khanna, Dinesh Khanna, Gout, 2013,

    CrossRef

  217. 217
    Fernando Perez-Ruiz, Ane Altuna, Joana Atxotegi, Gout, 2013,

    CrossRef

  218. 218
    A. Cotten, T. Pascart, B. Cortet, Imagerie Musculosquelettique : Pathologies Générales, 2013,

    CrossRef

  219. 219
    Dinesh Khanna, Puja P. Khanna, John D. Fitzgerald, Manjit K. Singh, Sangmee Bae, Tuhina Neogi, Michael H. Pillinger, Joan Merill, Susan Lee, Shraddha Prakash, Marian Kaldas, Maneesh Gogia, Fernando Perez-Ruiz, Will Taylor, Frédéric Lioté, Hyon Choi, Jasvinder A. Singh, Nicola Dalbeth, Sanford Kaplan, Vandana Niyyar, Danielle Jones, Steven A. Yarows, Blake Roessler, Gail Kerr, Charles King, Gerald Levy, Daniel E. Furst, N. Lawrence Edwards, Brian Mandell, H. Ralph Schumacher, Mark Robbins, Neil Wenger, Robert Terkeltaub, 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis, Arthritis Care & Research, 2012, 64, 10
  220. 220
    Thomas Bardin, Pascal Richette, Crystal arthritis: New ACR guidelines for gout management hold some surprises, Nature Reviews Rheumatology, 2012, 9, 1, 9

    CrossRef

  221. 221
    Jasvinder A Singh, Emerging therapies for gout, Expert Opinion on Emerging Drugs, 2012, 17, 4, 511

    CrossRef

  222. 222
    Fernando Perez-Ruiz, Ana Maria Herrero-Beites, Evaluation and Treatment of Gout as a Chronic Disease, Advances in Therapy, 2012, 29, 11, 935

    CrossRef

  223. 223
    H. Ralph Schumacher, Guidelines and Algorithms, Journal of Clinical Rheumatology, 2012, 18, 8, 387

    CrossRef

  224. 224
    Rakhi Seth, Alison SR Kydd, Rachelle Buchbinder, Claire Bombardier, Christopher J Edwards, Allopurinol for chronic gout, The Cochrane Library,
  225. 225
    Alison SR Kydd, Rakhi Seth, Rachelle Buchbinder, Christopher J Edwards, Claire Bombardier, Uricosuric medications for chronic gout, The Cochrane Library,